Variantyx, the leader in high complexity hereditary disease testing, today announced that it has entered into a licensing agreement with IBM for technologies that leverage artificial intelligence for somatic analysis from which Variantyx intends to develop comprehensive tumor diagnostic solutions.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Coagulo Medical Technologies, an MIT-born startup that has developed the world’s first precision-medicine platform for comprehensive and targeted blood clotting management, today announced it has raised $6.5 million in financing from 20/20 HealthCare Partners, Sands Capital, Good Growth Capital, IAG Capital Partners and private investors. The Boston area diagnostics innovator also announced that it has been awarded a Small Business Innovation Research (SBIR) grant by the National Science Foundation to accelerate delivery of breakthrough innovations amid the global COVID–19 public health crisis, which has called attention to the limitations of conventional coagulation tests.
(via BioProcess International)
SQZ Biotechnologies says its technology can produce cell therapies in less than 24 hours compared to a month or more for current products and is looking to use IPO proceeds toward the completion of Phase I development of its lead therapeutic candidate.
– Hillel Bachrach, Jason Camm and Zafrira Avnur join EnClear Therapies Board of Directors —
— Investors include 20/20 HealthCare Partners, Amgen Ventures, Peter Thiel, Global Health Sciences (GHS) Fund, Christian Angermayer’s Presight Capital, and Dolby Ventures —